<DOC>
	<DOCNO>NCT01863069</DOCNO>
	<brief_summary>The primary objective determine tolerability new inhaled formulation interferon beta-1a give single dose , give per week 4 week , compare standard intramuscular ( IM ) AVONEX® give single dose . The additional objective : To determine pharmacokinetic ( PK ) property new inhaled formulation interferon beta-1a , use anti-viral cytopathic effect ( CPE ) assay human interferon-beta , give single dose , give per week 4 week , compare standard IM AVONEX® give single dose . To determine pharmacodynamic ( PD ) property new inhaled formulation interferon beta-1a , measure serum neopterin 2-microglobulin , give single dose , give per week 4 week , compare standard IM AVONEX® give single dose .</brief_summary>
	<brief_title>Avonex® : Safety , Blood Levels Effects</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must age 18 45 year , inclusive . Must body mass index ( BMI ) 19 28 kilograms/height ( ) 2 , inclusive , minimum body weight 50 kilogram ( screen baseline ) . Must give write informed consent . History severe allergic anaphylactic reaction . History hypersensitivity acetaminophen ( paracetamol ) ibuprofen . Subjects Part III study also exclude history hypersensitivity human albumin . History clinically significant ( determined investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease . History asthma , define wheezing , dyspnea , cough requiring treatment either inhaled beta2agonists , inhaled corticosteroid , inhale cromolyn sodium , oral steroid history chronic obstructive pulmonary disease ( include chronic bronchitis , bronchiectasis , emphysema ) . Abnormal screen full pulmonary function test ( PFTs ) baseline spirometry ( predict value European Coal Steel Community ( Quanjer , 1983 ) ) abnormal screen baseline oximetry , define one following : &lt; 80 % predict Forced expiratory volume ( FEV1 ) &lt; 80 % predict forced vital capacity ( FVC ) &lt; 70 % FEV1/FVC ratio &lt; 80 % predict total lung capacity ( TLC ) &lt; 80 % predicted diffusion capacity , correct hemoglobin ( DLCOcorr ) . Oxygen saturation &lt; 96 % room air rest . Inability perform pulmonary function test reproducible manner . Inability use Pulmonary Delivery System device correctly . Abnormal baseline screen dyspnea scale , define score equal great 1 modify Medical Research Council ( MRC ) scale . Fever ( body temperature &gt; 38 degree C ) symptomatic viral bacterial infection ( include upper respiratory infection ) within 1 week prior first day dose . Abnormal baseline screen blood test exceed limit define : Alanine transaminase ( ALT ) aspartate transaminase ( AST ) bilirubin &gt; 2x upper limit normal ( &gt; 2x ULN ) Total white blood cell count ( WBC ) &lt; 3700/mm3 Platelet count &lt; 150,000/mm³ Hemoglobin &lt; 12 g/dL Plasma Creatinine &gt; ULN Prothrombin time ( PT ) activate thromboplastin time ( aPTT ) &gt; ULN Positive hepatitis C antibody , hepatitis B surface antigen ( HBsAg ) , HIV antibody . An electrocardiogram ( ECG ) clinically significant abnormality ( determined investigator ) . A chest radiograph ( CXR ) clinically significant abnormality ( determined investigator ) . History epilepsy fit unexplained blackout . Treatment History Previous treatment interferon beta interferon alpha product . Treatment another investigational drug approve therapy investigational use within 3 month prior first day dose . Except contraceptive , vitamin/mineral supplement , acetaminophen ( paracetamol ) , and/or ibuprofen , treatment medication include overthecounter product within 48 hour prior first dose study drug . Miscellaneous History smoking within 6 month prior first day dose . Abnormal screen urine cotinine level ( define &gt; 100 ng/mL perform capillary column gasliquid chromatography ) . History drug alcohol abuse ( define investigator ) within 2 year prior first day dose . Blood donation ( one unit ) within 1 month prior first day dose . Vigorous exercise ( determined investigator ) within 48 hour prior first dose study drug . Alcohol use within 24 hour prior first dose study drug . Female subject currently pregnant breastfeed . For female subject , unless postmenopausal surgically sterile , unwillingness practice effective contraception , define investigator , study . The rhythm method use sole method contraception . Women consider become pregnant study exclude . Positive screening baseline urine drug screen Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule . Current enrollment study . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>inhale</keyword>
	<keyword>interferon beta-1a</keyword>
	<keyword>healthy subject</keyword>
</DOC>